Expansion unlocks innovative clinical development expertise for APAC biopharma sector
Cytel, a pioneer of adaptive clinical trial design and provider of advanced biometrics services, has expanded its operations into the Asia-Pacific region (APAC). This enables biotech and biopharma companies in APAC to have easier access to Cytel’s established biometrics and advanced statistical solutions.
APAC’s growing interest in complex innovative trial design can benefit from Cytel’s advanced methodologies and expertise. Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years. This expansion marks the latest step in Cytel’s journey to deliver advanced analytics capabilities to drug developers across the globe.
“New norms set during the COVID-19 pandemic have only fueled the industry’s expectations of accelerated drug development,” said James Matcham, Executive Strategic Consultant, Cytel, Australia. “But APAC-based developers’ efforts to adopt trial-optimising innovation have been stifled by the services currently on offer in the region — namely CROs with only regional reach or global CROs without specialised analytics knowledge. Cytel offers both a rich global network and decades of advanced analytics know-how — precisely what’s needed to help APAC customers execute advanced clinical trial designs, better foresee roadblocks, and get their products registered in regions beyond APAC.”
“There have been a number of advances in clinical research methods across APAC,” says Jing Ping Yeo, Vice President and Head of APAC at Cytel. “The market is at the point where we need the use of advanced biostatistics and real-world capabilities like those honed at Cytel. Combined with the power of Cytel’s trial design, simulation, and forecasting tools, this will have the potential to generate transformative collaboration and allow new medical assets developed in Asia to get to patients faster.”
